Visual function 5 years after optic neuritis

Experience of the optic neuritis treatment trial

Roy W. Beck, Jonathan D. Trobe, Pamela S. Moke, Michael C. Brodsky, Edward G. Buckley, Georgia A. Chrousos, James A. Goodwin, John R. Guy, Barrett Katz, David I. Kaufman, John L. Keltner, Mark J. Kupersmith, Neil R Miller, Silvia Orengo-Nania, Peter J. Savino, William T. Shults, Craig H. Smith, H. Stanley Thompson, Michael Wall

Research output: Contribution to journalArticle

Abstract

Objective: To assess the 5-year visual course, including the incidence of recurrent optic neuritis, in 454 patients enrolled in the Optic Neuritis Treatment Trial. Methods: Five-year follow-up vision testing, which included measures of visual acuity, contrast sensitivity, visual field, and color vision, was completed for 397 (87%) of the 454 patients. Results: Visual function test results in the eyes that experienced optic neuritis at study enrollment (affected eyes) were normal or only slightly abnormal after 5 years in most patients; the results did not significantly differ by treatment group (P=.37 for visual acuity). The visual acuity in the affected eyes was 20/25 or better in 87%, 20/25 to 20/40 in 7%, 20/50 to 20/190 in 3%, and 20/200 or worse in 3%. The recurrence of optic neuritis in either eye occurred in 28% of the patients and was more frequent in patients with multiple sclerosis (P=.001) and in patients without multiple sclerosis who were in the prednisone treatment group (P=.004). Most eyes with a recurrence retained normal or almost normal visual function. Conclusions: Most patients retained good to excellent vision in the 5 years following an attack of optic neuritis, even if the optic neuritis recurred. Recurrences were more frequent in patients with multiple sclerosis and in those treated with oral prednisone alone. The completion of the 5-year follow-up by the Optic Neuritis Treatment Trial cohort has not altered our management recommendations based on the results we reported earlier.

Original languageEnglish (US)
Pages (from-to)1545-1552
Number of pages8
JournalArchives of Ophthalmology
Volume115
Issue number12
StatePublished - 1997
Externally publishedYes

Fingerprint

Optic Neuritis
Visual Acuity
Multiple Sclerosis
Therapeutics
Prednisone
Recurrence
Color Vision
Contrast Sensitivity
Visual Fields
Incidence

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Beck, R. W., Trobe, J. D., Moke, P. S., Brodsky, M. C., Buckley, E. G., Chrousos, G. A., ... Wall, M. (1997). Visual function 5 years after optic neuritis: Experience of the optic neuritis treatment trial. Archives of Ophthalmology, 115(12), 1545-1552.

Visual function 5 years after optic neuritis : Experience of the optic neuritis treatment trial. / Beck, Roy W.; Trobe, Jonathan D.; Moke, Pamela S.; Brodsky, Michael C.; Buckley, Edward G.; Chrousos, Georgia A.; Goodwin, James A.; Guy, John R.; Katz, Barrett; Kaufman, David I.; Keltner, John L.; Kupersmith, Mark J.; Miller, Neil R; Orengo-Nania, Silvia; Savino, Peter J.; Shults, William T.; Smith, Craig H.; Thompson, H. Stanley; Wall, Michael.

In: Archives of Ophthalmology, Vol. 115, No. 12, 1997, p. 1545-1552.

Research output: Contribution to journalArticle

Beck, RW, Trobe, JD, Moke, PS, Brodsky, MC, Buckley, EG, Chrousos, GA, Goodwin, JA, Guy, JR, Katz, B, Kaufman, DI, Keltner, JL, Kupersmith, MJ, Miller, NR, Orengo-Nania, S, Savino, PJ, Shults, WT, Smith, CH, Thompson, HS & Wall, M 1997, 'Visual function 5 years after optic neuritis: Experience of the optic neuritis treatment trial', Archives of Ophthalmology, vol. 115, no. 12, pp. 1545-1552.
Beck RW, Trobe JD, Moke PS, Brodsky MC, Buckley EG, Chrousos GA et al. Visual function 5 years after optic neuritis: Experience of the optic neuritis treatment trial. Archives of Ophthalmology. 1997;115(12):1545-1552.
Beck, Roy W. ; Trobe, Jonathan D. ; Moke, Pamela S. ; Brodsky, Michael C. ; Buckley, Edward G. ; Chrousos, Georgia A. ; Goodwin, James A. ; Guy, John R. ; Katz, Barrett ; Kaufman, David I. ; Keltner, John L. ; Kupersmith, Mark J. ; Miller, Neil R ; Orengo-Nania, Silvia ; Savino, Peter J. ; Shults, William T. ; Smith, Craig H. ; Thompson, H. Stanley ; Wall, Michael. / Visual function 5 years after optic neuritis : Experience of the optic neuritis treatment trial. In: Archives of Ophthalmology. 1997 ; Vol. 115, No. 12. pp. 1545-1552.
@article{cf9621e24056430985eaa530940c4e2b,
title = "Visual function 5 years after optic neuritis: Experience of the optic neuritis treatment trial",
abstract = "Objective: To assess the 5-year visual course, including the incidence of recurrent optic neuritis, in 454 patients enrolled in the Optic Neuritis Treatment Trial. Methods: Five-year follow-up vision testing, which included measures of visual acuity, contrast sensitivity, visual field, and color vision, was completed for 397 (87{\%}) of the 454 patients. Results: Visual function test results in the eyes that experienced optic neuritis at study enrollment (affected eyes) were normal or only slightly abnormal after 5 years in most patients; the results did not significantly differ by treatment group (P=.37 for visual acuity). The visual acuity in the affected eyes was 20/25 or better in 87{\%}, 20/25 to 20/40 in 7{\%}, 20/50 to 20/190 in 3{\%}, and 20/200 or worse in 3{\%}. The recurrence of optic neuritis in either eye occurred in 28{\%} of the patients and was more frequent in patients with multiple sclerosis (P=.001) and in patients without multiple sclerosis who were in the prednisone treatment group (P=.004). Most eyes with a recurrence retained normal or almost normal visual function. Conclusions: Most patients retained good to excellent vision in the 5 years following an attack of optic neuritis, even if the optic neuritis recurred. Recurrences were more frequent in patients with multiple sclerosis and in those treated with oral prednisone alone. The completion of the 5-year follow-up by the Optic Neuritis Treatment Trial cohort has not altered our management recommendations based on the results we reported earlier.",
author = "Beck, {Roy W.} and Trobe, {Jonathan D.} and Moke, {Pamela S.} and Brodsky, {Michael C.} and Buckley, {Edward G.} and Chrousos, {Georgia A.} and Goodwin, {James A.} and Guy, {John R.} and Barrett Katz and Kaufman, {David I.} and Keltner, {John L.} and Kupersmith, {Mark J.} and Miller, {Neil R} and Silvia Orengo-Nania and Savino, {Peter J.} and Shults, {William T.} and Smith, {Craig H.} and Thompson, {H. Stanley} and Michael Wall",
year = "1997",
language = "English (US)",
volume = "115",
pages = "1545--1552",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Visual function 5 years after optic neuritis

T2 - Experience of the optic neuritis treatment trial

AU - Beck, Roy W.

AU - Trobe, Jonathan D.

AU - Moke, Pamela S.

AU - Brodsky, Michael C.

AU - Buckley, Edward G.

AU - Chrousos, Georgia A.

AU - Goodwin, James A.

AU - Guy, John R.

AU - Katz, Barrett

AU - Kaufman, David I.

AU - Keltner, John L.

AU - Kupersmith, Mark J.

AU - Miller, Neil R

AU - Orengo-Nania, Silvia

AU - Savino, Peter J.

AU - Shults, William T.

AU - Smith, Craig H.

AU - Thompson, H. Stanley

AU - Wall, Michael

PY - 1997

Y1 - 1997

N2 - Objective: To assess the 5-year visual course, including the incidence of recurrent optic neuritis, in 454 patients enrolled in the Optic Neuritis Treatment Trial. Methods: Five-year follow-up vision testing, which included measures of visual acuity, contrast sensitivity, visual field, and color vision, was completed for 397 (87%) of the 454 patients. Results: Visual function test results in the eyes that experienced optic neuritis at study enrollment (affected eyes) were normal or only slightly abnormal after 5 years in most patients; the results did not significantly differ by treatment group (P=.37 for visual acuity). The visual acuity in the affected eyes was 20/25 or better in 87%, 20/25 to 20/40 in 7%, 20/50 to 20/190 in 3%, and 20/200 or worse in 3%. The recurrence of optic neuritis in either eye occurred in 28% of the patients and was more frequent in patients with multiple sclerosis (P=.001) and in patients without multiple sclerosis who were in the prednisone treatment group (P=.004). Most eyes with a recurrence retained normal or almost normal visual function. Conclusions: Most patients retained good to excellent vision in the 5 years following an attack of optic neuritis, even if the optic neuritis recurred. Recurrences were more frequent in patients with multiple sclerosis and in those treated with oral prednisone alone. The completion of the 5-year follow-up by the Optic Neuritis Treatment Trial cohort has not altered our management recommendations based on the results we reported earlier.

AB - Objective: To assess the 5-year visual course, including the incidence of recurrent optic neuritis, in 454 patients enrolled in the Optic Neuritis Treatment Trial. Methods: Five-year follow-up vision testing, which included measures of visual acuity, contrast sensitivity, visual field, and color vision, was completed for 397 (87%) of the 454 patients. Results: Visual function test results in the eyes that experienced optic neuritis at study enrollment (affected eyes) were normal or only slightly abnormal after 5 years in most patients; the results did not significantly differ by treatment group (P=.37 for visual acuity). The visual acuity in the affected eyes was 20/25 or better in 87%, 20/25 to 20/40 in 7%, 20/50 to 20/190 in 3%, and 20/200 or worse in 3%. The recurrence of optic neuritis in either eye occurred in 28% of the patients and was more frequent in patients with multiple sclerosis (P=.001) and in patients without multiple sclerosis who were in the prednisone treatment group (P=.004). Most eyes with a recurrence retained normal or almost normal visual function. Conclusions: Most patients retained good to excellent vision in the 5 years following an attack of optic neuritis, even if the optic neuritis recurred. Recurrences were more frequent in patients with multiple sclerosis and in those treated with oral prednisone alone. The completion of the 5-year follow-up by the Optic Neuritis Treatment Trial cohort has not altered our management recommendations based on the results we reported earlier.

UR - http://www.scopus.com/inward/record.url?scp=0031441266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031441266&partnerID=8YFLogxK

M3 - Article

VL - 115

SP - 1545

EP - 1552

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 12

ER -